Back to top
more

Trinity Biotech (TRIB)

(Delayed Data from NSDQ)

$1.83 USD

1.83
4,235

0.00 (0.00%)

Updated Apr 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TRIB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Trinity Biotech PLC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 4 7 26 27 16
Receivables 14 16 16 23 21
Notes Receivable NA 0 0 0 0
Inventories 20 23 29 30 32
Other Current Assets 2 2 2 3 2
Total Current Assets 39 47 73 83 71
Net Property & Equipment 2 6 6 9 9
Investments & Advances 0 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges 2 4 4 4 6
Intangibles 16 35 36 34 44
Deposits & Other Assets 0 0 0 0 0
Total Assets 59 92 119 130 131
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 83 0 0
Accounts Payable 15 15 15 24 17
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 2 2 2 2
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities 0 0 0 1 0
Total Current Liabilities 15 17 100 27 19
Mortgages NA 0 0 0 0
Deferred Taxes/Income 2 5 5 5 7
Convertible Debt 15 14 0 0 0
Long-Term Debt 40 44 0 83 82
Non-Current Capital Leases NA 12 14 17 18
Other Non-Current Liabilities 11 2 0 1 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 83 94 119 133 126
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) 2 2 1 1 1
Capital Surplus 47 46 16 16 16
Retained Earnings -49 -27 13 11 16
Other Equity 1 1 -5 -5 -4
Treasury Stock 25 25 25 25 25
Total Shareholder's Equity -24 -2 0 -2 5
Total Liabilities & Shareholder's Equity 59 92 119 130 131
Total Common Equity 99,975 -2 0 -2 5
Shares Outstanding 7.60 7.60 4.10 4.10 4.80
Book Value Per Share 13,154.61 -0.29 -0.08 -0.54 0.98

Fiscal Year End for Trinity Biotech PLC falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,995 6 14 4
Receivables NA 14 15 14 14
Notes Receivable NA NA 0 0 0
Inventories NA 20 21 23 22
Other Current Assets NA 2 2 2 20
Total Current Assets NA 39 44 53 58
Net Property & Equipment NA 2 2 2 6
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA NA 0 0 0
Deferred Charges NA 2 2 1 4
Intangibles NA 16 16 16 21
Deposits & Other Assets NA 0 0 0 2
Total Assets NA 59 64 72 91
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 15 11 13 13
Current Portion Long-Term Debt NA NA 0 0 0
Current Portion Capital Leases NA NA 2 2 2
Accrued Expenses NA NA 0 0 0
Income Taxes Payable NA NA 0 0 0
Other Current Liabilities NA 0 0 0 1
Total Current Liabilities NA 15 13 15 16
Mortgages NA NA 0 0 0
Deferred Taxes/Income NA 2 2 2 5
Convertible Debt NA 15 14 14 14
Long-Term Debt NA 40 40 40 49
Non-Current Capital Leases NA NA 11 12 12
Other Non-Current Liabilities NA 1 2 2
Minority Interest (Liabilities) NA NA 0 0 0
Total Liabilities NA 83 81 83 98
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA 0 0 0
Common Stock (Par) NA 2 2 2 2
Capital Surplus NA 47 47 47 47
Retained Earnings NA -49 -42 -36 -31
Other Equity NA 1 1 1 1
Treasury Stock NA 25 25 25 25
Total Shareholder's Equity NA -24 -17 -11 -7
Total Liabilities & Shareholder's Equity NA 59 64 72 91
Total Common Equity 0 99,975 -17 -11 -7
Shares Outstanding 7.60 7.60 7.60 7.60 7.60
Book Value Per Share 0.00 13,154.61 -2.30 -1.50 -0.87